Brought to you by 
Mylan unsolicited offer to acquire Perrigo lapses
19 Sep 2017
Executive Summary
Mylan NV made an unsolicited offer to acquire public OTC and generic pharmaceuticals company Perrigo Co. PLC in a cash and stock transaction valued at $28.9bn. Perrigo shareholders would receive $205 in combined cash and Mylan stock representing a 24.2% premium. The Perrigo board is currently evaluating the unsolicited offer. The companies have had ongoing discussions over a potential combination over the past few years. If approved, this would be Mylan's largest M&A to date.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mylan unsolicited offer to acquire Perrigo lapses
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice